ClinicalTrials.gg
RecruitingNCT05183126Updated Jul 2, 2026

Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer

A Phase 4 interventional study of Paclitaxel and Paclitaxel in Breast Cancer, Metastatic Gastric Cancer and Esophageal Cancer, sponsored by University of Michigan Rogel Cancer Center. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by University of Michigan Rogel Cancer Center · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
22
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 373 studies testing paclitaxel in Breast Neoplasms — 40 open to participants now, 60 under way, 13 of them phase 3. Paclitaxel · Breast Neoplasms.

Planned enrollment
306th of 361
22 · median 60
Started
2022
with 13 others
Phase 4
10 of 373
5 open now
Primary completion
2026-11
later than 29 of 59 live
Registered
335th of 373
by date

Among the 373 studies testing paclitaxel in Breast Neoplasms, this one is the 306th largest by planned enrollment of the 361 interventional ones that give a count, is one of 14 that started in 2022, is one of 10 in phase 4, reaches primary completion later than 29 of the 59 other live ones, and was the 335th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

40 of the 373 studies testing paclitaxel in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

35 more — sign in →

By country, each count listing its studies:

All 40 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 373 studies testing paclitaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

The primary objective of this pharmacokinetics study is to compare the maximum concentration level of paclitaxel in patients with low/sarcopenic skeletal muscle area (SMA), at the end of a 2-3 hour paclitaxel infusion, to the maximum level in patients with normal SMA at the end of a standard 1-hour infusion with the goal of determining whether lengthening the infusion in patients with low/sarcopenic SMA normalizes the levels to those of patients with normal SMA.

Read the detailed description

Paclitaxel is an FDA-approved and commonly used standard of care agent for patients with early-stage breast cancer. This study will use the standard dose of 80 mg/m\^2, including the typical pre-medications as per University of Michigan Rogel Cancer Center institutional standard. The only investigational component of this study is lengthening the infusion duration from 1-hour to 2 or 3 hours for a single dose in patients with low SMA.

JAN2025 update, Paclitaxel is an FDA-approved and commonly used standard of care agent for patients with early-stage breast cancer or metastatic gastric or esophageal cancers.

03

Conditions studied

  • Breast Cancer
  • Metastatic Gastric Cancer
  • Esophageal Cancer

Keywords

  • pharmacokinetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Planned paclitaxel 80 mg/m\^2, 1-hour infusion
  • Evaluable computed tomography (CT) scan, positron emission tomography computed tomography (PET-CT) scan, or MRI scan (e.g. scan of the chest, abdomen, or pelvis for any indication w/in 1 year)
  • Female
  • ≥ 18 years old
  • Adequate organ function to receive paclitaxel treatment as defined in the protocol
  • Ability to understand and the willingness to sign a written

Exclusion criteria

Exclusion Criteria:

  • Concomitant administration of any moderate or strong inducer or inhibitor of CYP2C8, including rifampin or clopidogrel.
  • History of reaction to paclitaxel or any components of paclitaxel (e.g., Cremophor EL) that precludes continued treatment with standard dose and infusion length
  • Pregnant or nursing
  • Receiving any other dose (i.e., not 80 mg/m2) or infusion rate (i.e., not 60 minute infusion) either due to toxicity during a previous cycle or any other reason
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • Active comparator
    Normal SMA (>7310 mm^2)

    Standard paclitaxel infusion time.

    Drug: Paclitaxel

  • Experimental
    Low SMA (5120 - 7310 mm^2) and Sarcopenic SMA (<5120 mm^2)

    Adjusted paclitaxel infusion time during only one dose; standard paclitaxel infusion time for all other doses.

    Drug: Paclitaxel

Interventions

  • Weekly intravenous (IV) infusion of a standard dose of paclitaxel 80 mg/m\^2. Dose 1 is a 90-minute infusion. All other doses administered as a 1-hour infusion for a total of 12 weekly doses.

    Also known as: Taxol

  • Weekly intravenous (IV) infusion of a standard dose of paclitaxel 80 mg/m\^2. Dose 1 is a 90-minute infusion. During doses 2-12, patients with low SMA will receive one 2-hour infusion and patients with sarcopenic SMA will receive one 3-hour infusion. All other doses during weeks 2-12 are standard infusion time.

    Also known as: Taxol

06

What researchers measure

Primary outcomes

  1. Maximum concentration (Cmax) of paclitaxel plasma

    Compare Cmax in patients with lower SMA with an adjusted infusion duration (i.e., 2-hour or 3-hour) to that of patients with normal SMA receiving standard 1-hour infusion. Blood samples for pharmacokinetic analysis will be collected within 5 minutes prior to the end of SMA-based and standard paclitaxel infusions. Measurement of plasma paclitaxel concentration for Cmax will be conducted using a liquid chromatography/mass spectroscopy assay.

    Time frame: Up to week 12

Secondary outcomes

  1. Two- to three-hour Cmax vs. one-hour Cmax in low SMA patients

    To compare Cmax in patients with lower SMA when receiving adjusted infusion duration (i.e., 2-hour or 3-hour) versus standard 1-hour infusion. Blood samples for pharmacokinetic analysis will be collected within 5 minutes prior to the end of SMA-based and standard paclitaxel infusions. Measurement of plasma paclitaxel concentration for Cmax will be conducted using a liquid chromatography/mass spectroscopy assay.

    Time frame: Up to week 12

  2. One-hour Cmax in normal SMA patients vs. one-hour Cmax in low SMA patients

    To compare Cmax in patients with lower SMA versus patients with normal SMA receiving when both receive standard 1-hour infusion. Blood samples for pharmacokinetic analysis will be collected within 5 minutes prior to the end of standard 1-hour paclitaxel infusions in both groups. Measurement of plasma paclitaxel concentration for Cmax will be conducted using a liquid chromatography/mass spectroscopy assay.

    Time frame: Up to week 12

07

Study locations

1 of 1 sites recruiting
  • University of Michigan Rogel Cancer Center
    Ann Arbor, Michigan 48109, United States
    Recruiting
    • Daniel L Hertz, PharmD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Nov 2026, 56 months after the start.

Of 110 non-industry phase 4 interventional studies under Breast Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's planned 56 months is above that.

Counting every sponsor, half of 130 studies reached it within 42 months; a quarter within 20 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2021
First posted
Jan 10, 2022
StartActual
Mar 28, 2022
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05183126
Responsible party
Sponsor
First posted
Jan 10, 2022
Start date
Mar 28, 2022
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Jul 2, 2026

Study contacts

Cancer AnswerLine
Contact
CancerAnswerLine@med.umich.edu
800-865-1125
Daniel L Hertz, PharmD, PhD
principal investigator · University of Michigan Rogel Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paclitaxel

Start the discussion